Beta Bionics and the promise of autonomy
A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
Big medtech's share price bloodbath
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
A radical strategy for Medtronic
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
ADA 2020 – Medtronic leads Insulet, but things could change
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
